A Phase 2 Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The study consists of two parts. Part 1 determines the safety and tolerability of BGB-11417
monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of BGB-11417
monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of
BGB-11417 monotherapy at the recommended Phase 2 dose with recommended ramp-up schedule from
Part 1.